BACKGROUND: Patients with peripheral arterial disease often undergo peripheral endovascular revascularization (PER) to alleviate symptoms. Despite the growth of PER, little information exists quantifying the health status benefits after the procedure. METHODS AND RESULTS: From February 2001 to August 2004, 477 consecutive patients underwent PER for symptomatic peripheral arterial disease. Of these, 300 consented to participate in a longitudinal follow-up study of their health status. Health status was quantified with the disease-specific Peripheral Artery Questionnaire and the generic Short Form-12 and the EuroQol 5 Dimensions (EQ5D)questionnaire. Scores range from 0 to 100; higher scores represent fewer symptoms and better health status. The average age of the cohort was 68+/-11 years (mean+/-SD); 186 (62%) were male, 288 (96%) were white, and 118 (39%) were diabetic. Clinical follow-up was attained in 99% of patients; health status assessments were made in 86%. Mean Peripheral Artery Questionnaire summary scores improved significantly after revascularization from 31+/-19 to 62+/-27 at 1 year (P<0.0001). Generic health status scores also improved significantly (P<0.001 for all). Despite a technically successful procedure in 98% of patients, 21% of patients did not achieve the minimal clinically important improvement of an 8-point change in Peripheral Artery Questionnaire Summary score after PER (35+/-19 at baseline versus 31+/-16 at 1 year; P=0.09). CONCLUSIONS: For most patients, significant and sustained improvements in symptoms, functioning, and quality of life occur after PER. Identifying and counseling patients less likely to benefit from PER is an important future research direction.
BACKGROUND:Patients with peripheral arterial disease often undergo peripheral endovascular revascularization (PER) to alleviate symptoms. Despite the growth of PER, little information exists quantifying the health status benefits after the procedure. METHODS AND RESULTS: From February 2001 to August 2004, 477 consecutive patients underwent PER for symptomatic peripheral arterial disease. Of these, 300 consented to participate in a longitudinal follow-up study of their health status. Health status was quantified with the disease-specific Peripheral Artery Questionnaire and the generic Short Form-12 and the EuroQol 5 Dimensions (EQ5D)questionnaire. Scores range from 0 to 100; higher scores represent fewer symptoms and better health status. The average age of the cohort was 68+/-11 years (mean+/-SD); 186 (62%) were male, 288 (96%) were white, and 118 (39%) were diabetic. Clinical follow-up was attained in 99% of patients; health status assessments were made in 86%. Mean Peripheral Artery Questionnaire summary scores improved significantly after revascularization from 31+/-19 to 62+/-27 at 1 year (P<0.0001). Generic health status scores also improved significantly (P<0.001 for all). Despite a technically successful procedure in 98% of patients, 21% of patients did not achieve the minimal clinically important improvement of an 8-point change in Peripheral Artery Questionnaire Summary score after PER (35+/-19 at baseline versus 31+/-16 at 1 year; P=0.09). CONCLUSIONS: For most patients, significant and sustained improvements in symptoms, functioning, and quality of life occur after PER. Identifying and counseling patients less likely to benefit from PER is an important future research direction.
Authors: Timothy P Murphy; Matthew R Reynolds; David J Cohen; Judith G Regensteiner; Joseph M Massaro; Donald E Cutlip; Emile R Mohler; Joselyn Cerezo; Niki C Oldenburg; Claudia C Thum; Suzanne Goldberg; Alan T Hirsch Journal: J Vasc Interv Radiol Date: 2013-07-29 Impact factor: 3.464
Authors: Ryan J Mays; Ivan P Casserly; Wendy M Kohrt; P Michael Ho; William R Hiatt; Mark R Nehler; Judith G Regensteiner Journal: J Vasc Surg Date: 2011-02-18 Impact factor: 4.268
Authors: Timothy P Murphy; Donald E Cutlip; Judith G Regensteiner; Emile R Mohler; David J Cohen; Matthew R Reynolds; Joseph M Massaro; Beth A Lewis; Joselyn Cerezo; Niki C Oldenburg; Claudia C Thum; Suzanne Goldberg; Michael R Jaff; Michael W Steffes; Anthony J Comerota; Jonathan Ehrman; Diane Treat-Jacobson; M Eileen Walsh; Tracie Collins; Dalynn T Badenhop; Ulf Bronas; Alan T Hirsch Journal: Circulation Date: 2011-11-16 Impact factor: 29.690
Authors: Poghni A Peri-Okonny; Jingyan Wang; Kensey L Gosch; Manesh R Patel; Mehdi H Shishehbor; David L Safley; J Dawn Abbott; Herbert D Aronow; Carlos Mena-Hurtado; Qurat-Ul-Ain Jelani; Yuanyuan Tang; Matthew Bunte; Clementine Labrosciano; John F Beltrame; John A Spertus; Kim G Smolderen Journal: Circ Cardiovasc Qual Outcomes Date: 2021-05-05
Authors: Poghni A Peri-Okonny; Sarthak Patel; John A Spertus; Elizabeth A Jackson; Ali O Malik; Jeremy Provance; Carlos Mena-Hurtado; Mehdi H Shishehbor; Vittal Hijjaji; Kensey L Gosch; Kim G Smolderen Journal: Am J Cardiol Date: 2020-10-13 Impact factor: 2.778
Authors: Rachel P Dreyer; Moniek van Zitteren; John F Beltrame; Robert Fitridge; Johan Denollet; Patrick W Vriens; John A Spertus; Kim G Smolderen Journal: J Am Heart Assoc Date: 2014-12-23 Impact factor: 5.501
Authors: Matthew R Reynolds; Patricia Apruzzese; Benjamin Z Galper; Timothy P Murphy; Alan T Hirsch; Donald E Cutlip; Emile R Mohler; Judith G Regensteiner; David J Cohen Journal: J Am Heart Assoc Date: 2014-11-11 Impact factor: 5.501
Authors: Matthew T D Dyer; Kimberley A Goldsmith; Linda S Sharples; Martin J Buxton Journal: Health Qual Life Outcomes Date: 2010-01-28 Impact factor: 3.186